All In Biotech

Drug Trial Radar · NCT05787587

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

216

Planned (sponsor's estimate)

Start

Apr 18, 2023

Primary completion

Oct 2026

Study completion May 2027

Sponsor

Lead sponsor
IDEAYA BiosciencesIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Mar 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

Conditions

  • Advanced or Metastatic Solid Tumors
  • Breast Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Endometrial Cancer
  • Colorectal Cancer
  • Head and Neck Cancers
  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)
  • NSCLC

Interventions

  • IDE-161Drug

    Oral Medication

  • PembrolizumabDrug

    Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDETime frame: Approximately 2 years
  2. Part 2 (Dose Expansion): To further assess the safety and tolerability of IDE monotherapy and in combination with pembrolizumab at the RDETime frame: Approximately 4 years
  3. Part 2 (Dose Expansion): To evaluate preliminary anti-tumor activity of IDE161 monotherapy or in combination with pembrolizumabTime frame: Approximately 4 years

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Phoenix, Arizona

  • The Angeles Clinic

    Los Angeles, California

  • Hoag Memorial Hospital

    Newport Beach, California

  • California Pacific Medical Center

    San Francisco, California

  • Sarah Cannon Research Institute

    Denver, Colorado

  • Yale University

    New Haven, Connecticut

  • Orlando Health

    Orlando, Florida

  • Emory University

    Atlanta, Georgia

  • OSF St Francis Medical Center

    Peoria, Illinois

  • Indiana University

    Indianapolis, Indiana

  • Dana Faber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Columbia University Medical Center

    New York, New York

  • Weil Cornell University

    New York, New York

  • Sarah Cannon Research Institute - Oklahoma University

    Oklahoma City, Oklahoma

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute - Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • MD Anderson

    Houston, Texas

  • NEXT Oncology

    Irving, Texas

  • NEXT Oncology

    San Antonio, Texas

  • START Mountain Region

    West Valley City, Utah

  • NEXT Oncology

    Fairfax, Virginia

  • Swedish Cancer Institute

    Seattle, Washington

  • University of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.